Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

President Bill Clinton honored with inaugural Tina's Wish Global Women's Health Award

Tina's Wish, the only nonprofit organization dedicated exclusively to funding research for the early detection of ovarian cancer, honored President Bill Clinton with the inaugural Tina's Wish Global Women's Health Award at a reception at the Waldorf Astoria New York on April 14th.

16 Apr 2015

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Nearly anyone touched by ovarian cancer will tell you: it's devastating. It's bad enough that cancer in almost 80 percent of patients reaches advanced stages before diagnosis, and that most patients are expected to die within five years. But just as painfully, roughly one quarter of women diagnosed have no warning that they are resistant to platinum-based chemotherapy, the main line of defense, nor that they will likely have 18 months to live.

16 Apr 2015

UAB research findings may lead to better treatment for women with HER2+ breast cancer

There are five subtypes of breast cancer, and they are distinct diseases with vastly different biologies that drastically alter their progression and responses to treatment. Understanding those differences is the starting point to a more effective, personalized treatment of breast cancer, which strikes more than 230,000 women in the U.S. each year.

16 Apr 2015

Women with ovarian cancer need to be tested for BRCA genes

The genes BRCA1 and BRCA2 play a significant role in hereditary breast and ovarian cancers. Recent media attention has focused on American actress Angelina Jolie's decision to have her ovaries and fallopian tubes surgically removed after genetic testing for such cancers.

16 Apr 2015

Vermillion, Kaiser Permanente partner to enhance diagnosis, treatment of ovarian cancer

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, today announced the initiation of a strategic partnership with Kaiser Permanente's Southern California Permanente Medical Group in order to enhance the diagnosis and treatment of ovarian cancer.

14 Apr 2015

VolitionRx adds three new laboratory automation systems to expedite sample analysis for its large ongoing clinical trials

Using its first installed robot, VolitionRx has recently completed the analysis of a first NuQ® assay on the complete set of 4,800 blood samples for its large retrospective, symptomatic population colorectal cancer study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark.

10 Apr 2015

Bright Pink, David's Bridal team up to raise awareness on breast and ovarian cancer

It's time to pucker up for a cause! Beginning today, David's Bridal will donate $1 (up to $100,000) to Bright Pink for every kiss sent on Instagram and Twitter using the hashtag #WithAKiss!

10 Apr 2015

Women with inherited BRCA1/2 mutations at increased risk of breast and ovarian cancers

In a study that involved more than 31,000 women who are carriers of disease-associated mutations in the BRCA1 or BRCA2 genes, researchers identified mutations that were associated with significantly different risks of breast and ovarian cancers, findings that may have implications for risk assessment and cancer prevention decision making among carriers of these mutations, according to a study in the April 7 issue of JAMA.

8 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

Mayo Clinic-led researchers combine genetic variants to improve identification of women with breast cancer

Recent large-scale genomic analyses have uncovered dozens of common genetic variants that are associated with breast cancer. Each variant, however, contributes only a tiny amount to a person's overall risk of developing the disease.

6 Apr 2015

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Myriad Genetics, Inc. today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib).

2 Apr 2015

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen Ltd today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

2 Apr 2015

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canadian and American health-care professionals will work together to study the effectiveness of advanced integrative oncology (AIO) treatment for patients with late stage cancer. AIO treatment includes elements of conventional and naturopathic medicine.

31 Mar 2015

Researchers identify potential drug molecule that kills cancer cells

The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions are made.

31 Mar 2015

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

US-Australian drug discovery company, Novogen Ltd, and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.

30 Mar 2015

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.

30 Mar 2015

Combination treatment improves outcomes in women with ovarian cancer

Medical researchers are always looking for ways to prevent or cure cancer. Given the complexity of this disease, reaching these milestones has been difficult.

30 Mar 2015

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman's tumor and extend the time period between initial treatment and the cancer's return.

29 Mar 2015

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

26 Mar 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

25 Mar 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

President Bill Clinton honored with inaugural Tina's Wish Global Women's Health Award

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

UAB research findings may lead to better treatment for women with HER2+ breast cancer

Women with ovarian cancer need to be tested for BRCA genes

Vermillion, Kaiser Permanente partner to enhance diagnosis, treatment of ovarian cancer

VolitionRx adds three new laboratory automation systems to expedite sample analysis for its large ongoing clinical trials

Bright Pink, David's Bridal team up to raise awareness on breast and ovarian cancer

Women with inherited BRCA1/2 mutations at increased risk of breast and ovarian cancers

MabVax closes $11.6 million in private placement

Mayo Clinic-led researchers combine genetic variants to improve identification of women with breast cancer

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Researchers identify potential drug molecule that kills cancer cells

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

Combination treatment improves outcomes in women with ovarian cancer

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in